Classic Antiphospholipid and Antiphosphatidylserine Antibody Profile in Suspected Antiphospholipid Antibody Syndrome Patient by Suryadi, Angga J & Sumapradja, Kanadi
Research  Article
Classic Antiphospholipid and Antiphosphatidylserine Antibody Profile
in Suspected Antiphospholipid Antibody Syndrome Patient
Gambaran Hasil Pemeriksaan Antibodi Antifosfolipid Klasik dan Anti
Fosfatidilserin pada Pasien yang Dicurigai Sindrom Antifosfolipid
Angga J Suryadi, Kanadi Sumapradja
Department of Obstetrics and Gynecology
 Faculty of Medicine Universitas Indonesia/
Dr. Cipto Mangunkusumo Hospital
Jakarta
INTRODUCTION
Intra Uterine Fetal Death (IUFD) was defined as a
fetal death which occurs in more than 20 weeks of
gestational age. Several factors underlie this condi-
tion such as fetus (chromosomal abnormality, in-
fection), placenta (placental abruption, placental
insufficiency), or maternal (metabolic disorder hy-
percoagulability state, etc.).1
 Hypercoagulable state is one of IUFD common
causes from maternal factors which are due to the
antiphospholipid syndrome (APS). This syndrome
is an autoimmune disease characterized by the
presence of antiphospholipid antibodies (aPL) and
at least one of clinical manifestations, such as ar-
terial or venous thrombosis or fetal death.2 The in-
cidence of APS in women experiencing IUFD was
quite high around 20-40%.3,4 The perinatal morta-
lity rate in Indonesia was generally about 77 per
1,000 live births whereas 30 stillborn fetuses were
caused by APS.5
Abstract
Objective: To compare the classic examination results of antiphos-
pholipid (aPS) and antiphospatidylserine (aPL) antibody profile to
establish the diagnosis from suspected antiphospholipid antibody
syndrome (APS) patient in order to state the subsequent treatment
strategies.
Method: This descriptive cross-sectional study design was con-
ducted at outpatient clinics of Dr. Cipto Mangunkusumo Hospital
(RSCM) from January to December 2015. The laboratory test was
held in Clinical Pathology Laboratory RSCM/Faculty of Medicine
Universitas Indonesia (FKUI) and in corporation with Prodia labo-
ratory.
Result: All of normal patients did not have positive result in any
laboratory examination (Lupus Anti-coagulant (LA), anticardiolipin
(aCL), anti-2 glycoprotein I (anti-2GPI), and aPS). In patient sus-
pected APS, 11 (37.1%) patients had positive aCL, 7 (25.9%) pa-
tients had positive anti-2GPI, and 11 (37.1%) patients had positive
aPS. The most positive cross laboratory examination was between
aCL and aPS (25.9%). In this study, we found the most positive test
result was aCL and aPS (62.9%). From this study, suspected APS pa-
tient who had negative result in classic laboratory examination, but
showing the positive result in aPS was in 5 (18.5%) patients.
Conclusion: All normal pregnant patients do not have any positive
classic examination and aPS. Meanwhile, in patients with suspected
APS, less than 20% patients show positive result of aPS with nega-
tive result in classic laboratory examination.
[Indones J Obstet Gynecol 2016; 4-3: 138-141]
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Abstrak
Tujuan: Untuk memberikan perbandingan hasil dari pemeriksaan
klasik antibodi antifosfotidilserin (aPL) dan antifosfolipid (aPS) untukmenegakkan diagnosis tersangka sindrom antibodi antifosfolipid se-
hingga dapat menentukan rencana tata laksana berikutnya.
Metode: Penelitian dengan desain potong lintang deskriptif ini di-
lakukan di Rumah Sakit Dr. Cipto Mangunkusumo (RSCM) pada bulan
Januari 2015 sampai Desember 2015. Pemeriksaan laboratorium di-lakukan di laboratorium Patologi Klinik RSCM - Fakultas Kedokteran
Universitas Indonesia dan laboratorium riset Prodia.
Hasil: Semua pasien hamil normal tidak memiliki satu pun pemerik-
saan klasik (antikoagulan lupus (LA), antikardiolipin (aCL), anti-2glikoprotein I (anti-2GPI) serta aPS) yang positif. Pada pasien yang
dicurigai APS, 11 (37,1%) pasien memiliki pemeriksaan aCL yang po-
sitif, 7 (25,9%) pasien memiliki pemeriksaan anti-2GPI positif, dan 11(37,1%) pasien memiliki pemeriksaan aPS yang positif. Hasil silang pe-
meriksaan aPL positif terbanyak adalah antara aCL dan aPS yaitu se-besar 25,9%. Pada penelitian ini didapatkan dua pemeriksaan labora-
torium yang positif terbanyak (62,9%), yaitu aCL dan aPS. Dari peneli-
tian ini, didapatkan pada pasien yang dicurigai APS tetapi memilikihasil negatif terhadap aCL, anti-2GPI, dan LA, ternyata sebanyak 5
(18,5%) pasien memiliki hasil positif pada pemeriksaan aPS.
Kesimpulan: Seluruh pasien hamil yang normal tidak menunjukkan
hasil pemeriksaan klasik dan aPS positif. Sementara itu, pasien yangdicurigai APS, hanya 20% yang menunjukkan hasil aPS positif dengan
hasil pemeriksaan klasik negatif.
[Maj Obstet Ginekol Indones 2016; 4-3: 138-141]
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The high incidence of IUFD due to APS makes
us to improve the knowledge in diagnosing and
performing subsequent management. To diagnose
APS, it takes at least 1 clinical criteria namely the
presence of one or more unknown causes from fe-
tal deaths at the over 10 weeks of gestational age
and supported by laboratory criteria which is the
presence of aPL.2,6,7 There is variety of already
known aPL, such as lupus anticoagulant (LA), an-
ticardiolipin (aCL), antiphosphatidylserine (aPL),
antiphosphatidylethanolamine (aPE), many more.8
The LA and aCL antibodies are first discovered
to diagnose APS. One of the screening for LA was
through the examination of activated partial
thromboplastin time (aPTT).2 Meanwhile, the
examination of aCL has progressed from time to
time. Many studies have shown that aCL was not
directly bind to the negatively charged phos-
pholipids, but it stuck to the beta-2 Glycoprotein I
(2GPI), a plasma protein or "cofactor" which was
attached directly to negatively charged phos-
pholipids.3
However, patients sometimes show negative
classic examination results (aPL aCL, anti- 2GPI,
and LA) in clinically suspected APS. Thus, some
experts put those patients in the category of sero-
negative APS.9 Meanwhile, other experts are oppo-
site to the above categories which they suggests
that it is caused by aPL contained on the patient
instead of an antibody to cardiolipin, and 2GPI;
however, the antibodies to phosphatidylserine
(aPL) is part of the inner cell membrane.10,11 Study
by Matzner, et al. stated that aPL was most often
identified as the aPS (20.5%) and aPE (19.1%).12
Therefore, this study aims to compare the classic
examination results of antiphospholipid (aPS) and
antiphospatidylserine (aPL) antibody profile to
establish the diagnosis from suspected antiphos-
pholipid antibody syndrome (APS) patient in order
to state the subsequent treatment strategies.
METHODS
This study was conducted with a descriptive cross-
sectional design at outpatient clinics of dr. Cipto
Mangunkusumo Hospital (RSCM) from January to
December 2015. The laboratory test was taken in
Clinical Pathology laboratory RSCM/Faculty of Me-
dicine Universitas Indonesia (FKUI) and Prodia
laboratory. The inclusion criteria for the group of
normal pregnancy were the one who never expe-
rienced any of the Sydney criteria; while, group of
APS were the patients suspected of APS (fetus
death at more than 10 weeks of gestational age) in
accordance with one of the clinical criteria for APS
(revised in 2006 in Sydney). The exclusion criteria
for normal pregnancies were women having expe-
rienced one or more clinical episodes of arterial
thrombosis, venous or small blood vessels in the
tissue or any organ; and patients with infection (fe-
ver, or other symptoms of infection). The exclusion
criteria for APS were patients with genetic abnor-
malities (abnormal morphology of the parents); fe-
tus with abnormalities (confirmed by direct exami-
nation and the results of ultrasonography); pa-
tients with the quality of the gametes were not
good (to be seen on the patients aged > 35 years
old); patients with metabolic disorders (elevated
blood sugars more than 200). We did the consecu-
tive sampling for all patients who come in and
meet the inclusion criteria in the study until the
required number of subjects met.
RESULTS
In this study, we got 54 patients who met the in-
clusion criteria as study subjects. Of the 54 pa-
tients, 27 patients had normal pregnancy and 27
patients with suspected APS. As seen in Table 1, all
normal pregnant patients did not have any positive
of classic examination (LA, aCL and anti-2GPI) and
aPS.
Table 1. Classic aPL Examination Profile (aCL, anti- 2GPI,
and LA), and aPS in Normal and Suspected APS Patients
Antibody
Examination
Normal P;regnancy
(n=27)
n (%)
Suspected APS
(n=27)
n (%)
LA
Normal 27 (100) 25 (92.5)
Prolonged 0 (0) 2 (7.5)
aCL
Negative 27 (100) 17 (62.9)
Positive 0 (0) 11 (37.1)
anti-2GPI
Negative 27 (100) 20 (74.1)
Positive 0 (0) 7 (25.9)
aPS
Negative 27 (100) 17 (62.9)
Positive 0 (0) 11 (37.1)
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In patients with suspected APS, 11 (37.1%) pa-
tients had positive aCL examination, 7 (25.9%) pa-
tients had positive anti-2GPI examination, and 11
(37.1%) patients had positive aPS examination. We
tried to look at the classic cross-examination of aPL
(aCL, anti- 2GPI, and LA), and aPS in patients sus-
pected of having APS (results not normal or posi-
tive). From this study, it was found in 2 (7.5%) pa-
tients having positive cross between LA and aCL,
LA and anti-2GPI, as well as LA and aPS. The most
positive aPL of cross-examination result was
between aCL and aPS (25.9%) (Table 2).
Table 3. Classic aPL Examination Profile (aCL, anti-2GPI,
and LA), and aPS in Suspected APS Patients (only one
positive examination)
Antibody Examination Suspected APS n (%)
LA 2 (92.5)
aCL 11 (62.9)
anti-2GPI 7 (74.1)
aPS 11 (62.9)
In this study, two most positive laboratory result
(62.9%) were aCL and aPS (Table 3). From this
study, it was found that in patients with suspected
APS, it depicted the negative result against aCL,
anti-2GPI, and LA; nevertheless, it showed the
positive result on aPS examination as many as five
(18.5%) patients (Table 4).
Table 4. The Proportion of Patients who were Clinically
Suspected of Having APS which Had Negative aPL Classic
Examination Results (aCL, anti-2GPI, and LA), but Positive
aPS Result
Antibody Examination Suspected APS n (%)
aPS 5 (18.5)
DISCUSSION
In patients with suspected APS, 11 (37.1%) pa-
tients had positive aCL examination, 7 (25.9%) pa-
tients had positive anti-2GPI examination, and 11
(37.1%) patients had positive aPS examination. We
intend to compare the aPL level of subjects sus-
pected APS with normal pregnant subjects which
aims to prove that the levels of aPL in normal preg-
nancy will not increase.
From this study, it was found in 2 (7.5%) pa-
tients had a positive cross between LA and aCL, LA
and anti-2GPI, as well as LA and aPS. This was
because only two patients were positive for LA
examination. However, sometimes, patients with
clinically suspected APS has negative result of clas-
sic examination aPL (aCL, anti-2GPI, and LA).
Some researchers put it in the category of sero-
negative aPS.9 The diagnosis of seronegative an-
tiphospholipid syndrome (SN-APS) is used in pa-
tients with clinical manifestations leading to the
APS, but classic examination results of aPL (aCL,
anti-2GPI, and LA) are persistently negative. Until
now, the best management of these patients is still
unclear. Examination of aPL in addition to classical
examination may improve the ability to diagnose
APS. However, the availability of aPL in routine
laboratory examination is still limited. Patients
with typical clinical manifestations of APS, it can
have negative results on the examination of LA in-
cluding IgG and IgM aCL and anti-2GPI. However,
there are several considerations which some pa-
tients with negative results on classic examination
may have antibodies against other phospholipid
membranes, such as phosphatidylserine (PL),
phosphatidic acid (PA), phosphatidylinositol (PI),
phosphatidylethanolamine (PE) which are not in-
cluded in the examination of blood routine.9,10,13
This study investigated the antibodies to phospha-
tidylserine (PS) as a part of the inner cell mem-
Table 2. Cross-examination Profile of Classic aPL Examination (aCL, anti-2GPI, and LA) and aPS in Suspected APS Patients
     (abnormal or positive result)
Examination LA n (%) aCL n (%) anti­2GPI n (%) aPS n (%)
LA n (%) 2 (7.5) 2 (7.5) 2 (7.5)
aCL n (%) 3 (11.1) 7 (25.9)
anti­2GPI n (%) 3 (11.1)
aPS n (%)
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brane.10,11 From this study, it was found that in pa-
tients with suspected APS, but having negative re-
sult against aCL, anti-2GPI, and LA, it turned out
as much 5 (18.5%) patients having positive results
on aPS examination (Table 4). This was consistent
to study conducted by Matzner, et al. which
showed aPL as the most frequently identified anti-
body and followed by aPS.12
The diagnosis of SN-APS is an important issue
for the clinician to decide additional examination
in diagnosing APS. If the classic examination has a
negative result and a thorough evaluation of ge-
netic and acquired conditions leading to thrombo-
sis can be ruled out, we need the additional exami-
nation. In the future, it is possible that aPL as the
additional examination will be included into the
criteria.9,11
The strength of this study was that we tried to
see the profile of clinically APS suspected patient
who pointed out the negative of standard labora-
tory result, but positive result of APS. Unfortu-
nately, the limitation of this study was we had not
done the repeated serology examination after 12
weeks applied as gold standard. The study did not
examine patients who had a trip of APS positive
test results and did not review the outcome of
pregnancy.
CONCLUSION
All normal pregnant patients do not have any posi-
tive classic examination and aPS. Meanwhile, in pa-
tients with suspected APS, less than 20% patients
show positive result of aPS with negative result in
classic laboratory examination.
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